Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China
- PMID: 27029033
- PMCID: PMC5008277
- DOI: 10.18632/oncotarget.8307
Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China
Abstract
Purpose: To analyze the clinical performance of p16/Ki-67 dual-stained cytology identifying high-grade cervical intraepithelial neoplasia (CIN2+) in Chinese women.
Methods: 1079 women attending ongoing cervical cancer screening and 211 "enriched" women aged ≥30yrs with biopsy-confirmed CIN2+ from five Chinese hospitals were enrolled during year 2014-2015. Cervical specimens were collected for high-risk human papillomavirus (HR-HPV) DNA analysis, Liquid-based cytology (LBC) and p16/Ki-67 dual staining. Colposcopy and biopsy were performed on women with any abnormal result.
Results: p16/Ki-67 positivity increased with histologic severity. It was 18.4%(183/996) in normal histology, 54.0%(34/63) in CIN1, 81.0%(34/42) in CIN2, 93.3%(111/119) in CIN3, 71.4% (5/7) in adenocarcinoma and 95.2%(60/63) in squamous cell carcinoma. Compared with the HR-HPV negatives, p16/Ki-67 expression was significantly higher in the HPV16/18 positive (OR: 35.45(95%CI: 23.35-53.84)) and other 12 HR-HPV types positive group (OR: 8.01(95%CI: 5.81-11.05). The sensitivity and specificity of p16/Ki-67 to detect CIN2+ in the entire population were 90.9% and 79.5%, respectively. In women with ASC-US and LSIL, sensitivity and specificity for detection of CIN2+ were 87.5% and 66.4%, respectively, with a referral rate of 43.8%. In women who tested positive for HR-HPV, sensitivity and specificity of dual-staining for detection of CIN2+ were 92.7% and 52.7%, respectively, and the referral rate was 68.7%.
Conclusions: p16/Ki-67 dual-stained cytology provided a high sensitivity and moderate specificity to detect underlying cervical precancer and cancers in various settings, and might be considered as an efficient screening tool in China.
Keywords: Chinese women; Pathology Section; cervical cancer; human papillomavirus; p16/Ki-67 dual staining.
Conflict of interest statement
All the authors declare that they have no competing interests.
Similar articles
-
Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.Int J Cancer. 2021 Jan 15;148(2):492-501. doi: 10.1002/ijc.33250. Epub 2020 Aug 24. Int J Cancer. 2021. PMID: 32781481
-
Expression of p16/Ki-67 in ASC-US/LSIL or Normal Cytology with Presence of Oncogenic HPV DNA.Anticancer Res. 2015 Nov;35(11):6291-5. Anticancer Res. 2015. PMID: 26504065
-
Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology.Cancer Cytopathol. 2019 Mar;127(3):169-180. doi: 10.1002/cncy.22103. Epub 2019 Feb 27. Cancer Cytopathol. 2019. PMID: 30811902
-
Management of high-risk HPV-positive women for detection of cervical (pre)cancer.Expert Rev Mol Diagn. 2016 Sep;16(9):961-74. doi: 10.1080/14737159.2016.1217157. Epub 2016 Aug 5. Expert Rev Mol Diagn. 2016. PMID: 27459506 Review.
-
The Role of Cytology in the 21st Century: The Integration of Cells and Molecules.Acta Cytol. 2016;60(6):540-542. doi: 10.1159/000449402. Epub 2016 Oct 28. Acta Cytol. 2016. PMID: 27788516 Review.
Cited by
-
Enhancing Cervical Cancer Screening: Review of p16/Ki-67 Dual Staining as a Promising Triage Strategy.Diagnostics (Basel). 2024 Feb 19;14(4):451. doi: 10.3390/diagnostics14040451. Diagnostics (Basel). 2024. PMID: 38396493 Free PMC article. Review.
-
Evaluation of the clinical performance of p16/Ki-67 dual-staining cytology for cervical lesion detection in premenopausal and postmenopausal Chinese women.J Cancer Res Clin Oncol. 2023 Sep;149(12):10645-10658. doi: 10.1007/s00432-023-04938-1. Epub 2023 Jun 11. J Cancer Res Clin Oncol. 2023. PMID: 37302113
-
Mathematical Modelling of Cervical Precancerous Lesion Grade Risk Scores: Linear Regression Analysis of Cellular Protein Biomarkers and Human Papillomavirus E6/E7 RNA Staining Patterns.Diagnostics (Basel). 2023 Mar 13;13(6):1084. doi: 10.3390/diagnostics13061084. Diagnostics (Basel). 2023. PMID: 36980391 Free PMC article.
-
Comparative Assessment of p16/Ki-67 Dual Staining Technology for cervical cancer screening in women living with HIV (COMPASS-DUST)-Study protocol.PLoS One. 2023 Jan 26;18(1):e0278077. doi: 10.1371/journal.pone.0278077. eCollection 2023. PLoS One. 2023. PMID: 36701329 Free PMC article.
-
Condyloma acuminatum mimicking cervical cancer in a pregnant woman and treatment with cryotherapy: A case report.Medicine (Baltimore). 2022 Dec 9;101(49):e32273. doi: 10.1097/MD.0000000000032273. Medicine (Baltimore). 2022. PMID: 36626521 Free PMC article.
References
-
- Wen C. China's plans to curb cervical cancer. Lancet Oncol. 2005;6:139–141. - PubMed
-
- Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, Sellors JW, Franceschi S, Qiao YL, Castle PE. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010;11:1160–1171. - PMC - PubMed
-
- Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–1101. - PubMed
-
- Fields RP. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med. 2008;358:642–643. 643-644. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
